HBV Citations List: January 2025

Literature Citations

1. Discovery of Pentacyclic Triterpene Conjugates as HBV Polymerase/NTCP Dual-Targeting Inhibitors with Potent Anti-HBV Activities. Chen, Y., M. Duan, J. Xu, A. Duan, H. Yang, H. Tao, S. Tian, Z. Zhou, W. Li, H. Tao, Y. Zhu and Q. Zhu. Bioorganic Chemistry, 2025. 154: 108054. PMID[39700828].
[PubMed]. HBV_01_2025.

2. Identification of Peptide-Based Hepatitis B Virus Capsid Inhibitors Based on the Viral Core Protein. Fujimoto, J., K. Kawahara, K. Takeda, S. Takeo, K. Sato, K. Nakashima, N. Mase, M. Yokoyama, T. Suzuki and T. Narumi. Bioorganic and Medicinal Chemistry Letters, 2025. 117: 130054. ISI[001391002800001].
[WOS]. HBV_01_2025.

3. Synthesis and Antiviral Evaluation of 5-(4-Aryl-1,3-butadiyn-1-yl)-uridines and Their Phosphoramidate Pronucleotides. Saillard, E., O. Bourzikat, K. Assa, V. Roy and L. A. Agrofoglio. Molecules, 2025. 30(1): 96. ISI[001393620200001].
[WOS]. HBV_01_2025.

4. Antiviral Activity of HuaganJiedu Decoction (HGJDD) against Hepatitis B Virus (HBV) through FOXO4/ERK/HNF4α Signal Pathway. Tong, H., J. Zhang, L. Jiang, R. Qu, T. Lu and J. Hu. Journal of Ethnopharmacology, 2025. 340: 119238. PMID[39701219].
[PubMed]. HBV_01_2025.

Patent Citations

This month, no relevant HBV patents were identified.